Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer
Status:
Recruiting
Trial end date:
2021-01-31
Target enrollment:
Participant gender:
Summary
Anlotinib is a novel multi-target tyrosine kinase inhibitor (TKI) for tumor angiogenesis and
tumor cell proliferation. The efficacy of Anlotinib as a third-line or beyond therapy for
SCLC was confirmed in the ALTER1202 trial. The aim of this trial was to investigate the
prognostic value of Anlotinib plus platinum-etoposide in first-line treatment of
extensive-stage SCLC patients.